|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US6599910B1
(en)
|
1998-08-20 |
2003-07-29 |
Smithkline Beecham Corporation |
Substituted triazole compounds
|
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
JP2002528506A
(ja)
|
1998-11-04 |
2002-09-03 |
スミスクライン・ビーチャム・コーポレイション |
ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン
|
|
ES2384160T3
(es)
|
1999-01-13 |
2012-07-02 |
Bayer Healthcare Llc |
Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
PL199802B1
(pl)
|
1999-02-10 |
2008-10-31 |
Astrazeneca Ab |
Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
|
|
HUP0202682A3
(en)
|
1999-09-10 |
2003-03-28 |
Merck & Co Inc |
Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
|
|
ES2230171T3
(es)
|
1999-11-23 |
2005-05-01 |
Smithkline Beecham Corporation |
Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
|
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
DE60023025T2
(de)
|
1999-11-23 |
2006-07-13 |
Smithkline Beecham Corp. |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
|
WO2001038314A1
(en)
|
1999-11-23 |
2001-05-31 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
EP1274692B1
(en)
|
2000-04-07 |
2006-08-02 |
AstraZeneca AB |
Quinazoline compounds
|
|
BR0113056A
(pt)
|
2000-08-09 |
2003-07-08 |
Astrazeneca Ab |
Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
|
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
DE60111752T2
(de)
*
|
2000-08-31 |
2006-05-04 |
F. Hoffmann-La Roche Ag |
7-oxopyridoryrimidine
|
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6638926B2
(en)
*
|
2000-09-15 |
2003-10-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
EP1698627A1
(en)
|
2000-09-15 |
2006-09-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
WO2002024667A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Merck Patent Gmbh |
4-amino-quinazolines
|
|
BR0114021A
(pt)
*
|
2000-09-20 |
2003-08-19 |
Merck Patent Gmbh |
4-amino-quinazolinas
|
|
EP2404603A1
(en)
|
2000-10-23 |
2012-01-11 |
Glaxosmithkline LLC |
Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
|
|
SE0004054D0
(sv)
*
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6620482B2
(en)
*
|
2000-11-30 |
2003-09-16 |
Avturf Llc |
Safety system for airports and airfields
|
|
WO2002103115A2
(en)
*
|
2000-11-30 |
2002-12-27 |
Avturf L.L.C. |
Artificial turf for an airport filed
|
|
CA2432799C
(en)
*
|
2000-12-21 |
2008-08-19 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
GB0102668D0
(en)
*
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
|
JP2004521915A
(ja)
*
|
2001-02-02 |
2004-07-22 |
グラクソ グループ リミテッド |
Tgf過剰発現に対するピラゾール誘導体
|
|
WO2002062787A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Glaxo Group Limited |
Pyrazoles as tgf inhibitors
|
|
ES2280517T3
(es)
*
|
2001-03-23 |
2007-09-16 |
Bayer Pharmaceuticals Corporation |
Inhibidor de rho-cinasa.
|
|
JP4329003B2
(ja)
*
|
2001-03-23 |
2009-09-09 |
バイエル コーポレイション |
Rhoキナーゼ阻害剤
|
|
US7390808B2
(en)
|
2001-04-30 |
2008-06-24 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes
|
|
AU2002324450A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidines and uses thereof
|
|
WO2003000188A2
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
|
JP2004535437A
(ja)
|
2001-06-22 |
2004-11-25 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
DE60239558D1
(de)
|
2001-10-05 |
2011-05-05 |
Zalicus Inc |
Kombinationen für die behandlung von immun-entzündlichen erkrankungen
|
|
GB0124936D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124934D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
AU2002365611A1
(en)
*
|
2001-12-05 |
2003-06-17 |
F. Hoffmann - La Roche Ag |
Inflammation modulators
|
|
US20030187026A1
(en)
*
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
ES2305435T3
(es)
*
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
Inhibidores de la rho-quinasa.
|
|
DE60318177T2
(de)
*
|
2002-01-23 |
2008-10-09 |
Bayer Pharmaceuticals Corp., West Haven |
Rho-kinase inhibitoren
|
|
CA2473510A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
|
NZ534171A
(en)
|
2002-02-01 |
2007-06-29 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
|
MXPA04007697A
(es)
*
|
2002-02-06 |
2004-11-10 |
Vertex Pharma |
Compuestos de heteroarilo utiles como inhibidores de gsk-3.
|
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
|
ATE375980T1
(de)
|
2002-02-12 |
2007-11-15 |
Smithkline Beecham Corp |
Nicotinamide und deren verwendung als p38 inhibitoren
|
|
ATE468336T1
(de)
*
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US20030220336A1
(en)
*
|
2002-04-05 |
2003-11-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method of treating mucus hypersecretion
|
|
NZ536278A
(en)
*
|
2002-04-05 |
2007-05-31 |
Boehringer Ingelheim Pharma |
p38 kinase inhibitors for treating mucus hypersecretion associated with cystic fibrosis
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
US7629350B2
(en)
*
|
2002-04-19 |
2009-12-08 |
Smithkline Beecham Corporation |
Compounds
|
|
US7388009B2
(en)
*
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
|
BR0309669A
(pt)
*
|
2002-04-23 |
2005-03-01 |
Bristol Myers Squibb Co |
Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
|
|
DE60325469D1
(de)
*
|
2002-04-23 |
2009-02-05 |
Bristol Myers Squibb Co |
Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
|
|
AU2003229305A1
(en)
*
|
2002-05-17 |
2003-12-02 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
|
|
TW200400034A
(en)
*
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
US20040044020A1
(en)
*
|
2002-07-09 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
|
|
AU2003245989A1
(en)
|
2002-07-09 |
2004-01-23 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
|
EP1521747B1
(en)
*
|
2002-07-15 |
2018-09-05 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
|
US20040146509A1
(en)
*
|
2002-07-25 |
2004-07-29 |
Zhihe Li |
Methods for improvement of lung function using TGF-beta inhibitors
|
|
CA2494367A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methods for improvement of lung function using tgf-.beta. inhibitors
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
PT1532145E
(pt)
*
|
2002-08-02 |
2007-01-31 |
Vertex Pharma |
Composiçoes de pirazole úteis como inibidores de gsk-3
|
|
EP1548008A4
(en)
|
2002-08-23 |
2008-08-06 |
Kirin Pharma Kk |
COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
|
|
EP1558261A4
(en)
*
|
2002-10-31 |
2008-06-04 |
Israel State |
CHINAZOLINONE COMPOSITIONS TO REGULATE GENE EXPRESSION IN CONNECTION WITH PATHOLOGICAL PROCESSES
|
|
US20040138188A1
(en)
*
|
2002-11-22 |
2004-07-15 |
Higgins Linda S. |
Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
|
|
CA2506978A1
(en)
*
|
2002-11-22 |
2004-06-10 |
Scios, Inc. |
Method for counteracting a pathologic change in the b-adrenergic pathway
|
|
AU2003297460A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Scios, Inc. |
TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
|
|
AU2003290279A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2004065392A1
(en)
*
|
2003-01-24 |
2004-08-05 |
Smithkline Beecham Corporation |
Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
|
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
CL2004000409A1
(es)
*
|
2003-03-03 |
2005-01-07 |
Vertex Pharma |
Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
|
|
US7713983B2
(en)
*
|
2003-03-03 |
2010-05-11 |
Vertex Pharmaceuticals Incorporated |
Quinazolines useful as modulators of ion channels
|
|
EP1603908B1
(en)
*
|
2003-03-12 |
2008-06-11 |
Millennium Pharmaceuticals, Inc. |
Quinazoline derivatives as tgf-beta inhibitors
|
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
|
JP2006521398A
(ja)
|
2003-03-28 |
2006-09-21 |
サイオス・インコーポレーテツド |
TGFβの二−環式ピリミジン阻害剤
|
|
GB0307333D0
(en)
*
|
2003-03-29 |
2003-05-07 |
Astrazeneca Ab |
Therapeutic agent
|
|
GB0308185D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308186D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
US7763627B2
(en)
*
|
2003-04-09 |
2010-07-27 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
WO2004092144A2
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds useful as p38 kinase inhibitors
|
|
DK1626714T3
(da)
|
2003-05-20 |
2007-10-15 |
Bayer Pharmaceuticals Corp |
Dirarylurinstoffer mod sygdomme medieret af PDGFR
|
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
|
WO2005000298A2
(en)
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
5-membered heterocycle-based p-38 inhibitors
|
|
US20060241150A1
(en)
*
|
2003-06-06 |
2006-10-26 |
Weiner David B |
P38 kinase inhibitor compositions and methods of using the same
|
|
WO2004112710A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Millennium Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
|
|
CN1832928B
(zh)
|
2003-06-26 |
2012-07-04 |
诺瓦提斯公司 |
以5元杂环为基础的p38激酶抑制剂
|
|
WO2005003100A2
(en)
*
|
2003-07-03 |
2005-01-13 |
Myriad Genetics, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
DE602004029293D1
(de)
*
|
2003-07-25 |
2010-11-04 |
Novartis Ag |
p-38-Kinasehemmer
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
GB0318814D0
(en)
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
AU2004272348B2
(en)
|
2003-09-16 |
2008-09-04 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
US7244441B2
(en)
*
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
|
ES2436888T3
(es)
|
2003-09-26 |
2014-01-07 |
Exelixis, Inc |
Moduladores c-Met y métodos de uso
|
|
WO2005032481A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
|
US7901753B2
(en)
*
|
2003-11-12 |
2011-03-08 |
Avturf L.L.C. |
Synthetic runway surface system
|
|
US20050267182A1
(en)
*
|
2003-11-13 |
2005-12-01 |
Ambit Biosciences Corporation |
Urea derivatives as FLT-3 modulators
|
|
CA2548172A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
|
AU2004298486A1
(en)
|
2003-12-12 |
2005-06-30 |
Wyeth |
Quinolines useful in treating cardiovascular disease
|
|
SI1697356T1
(sl)
*
|
2003-12-16 |
2008-06-30 |
Pfizer Prod Inc |
Pirido(2,3-d)pirimidin-2,4-diamini kot zaviralci PDE 2
|
|
KR20070007055A
(ko)
*
|
2003-12-24 |
2007-01-12 |
사이오스 인코퍼레이티드 |
Tgf-베타 억제제를 이용한 악성 신경교종의 치료법
|
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
JP4121026B2
(ja)
*
|
2004-01-21 |
2008-07-16 |
富士フイルム株式会社 |
撮像装置および方法並びにプログラム
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
EP1734040A4
(en)
*
|
2004-03-23 |
2007-11-28 |
Banyu Pharma Co Ltd |
SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
|
|
BRPI0512261A
(pt)
*
|
2004-06-17 |
2008-02-26 |
Wyeth Corp |
antagonistas de receptor de hormÈnio liberador de gonadotropina
|
|
WO2006009736A1
(en)
*
|
2004-06-17 |
2006-01-26 |
Wyeth |
Processes for preparing gonadotropin releasing hormone receptor antagonists
|
|
US20050282756A1
(en)
*
|
2004-06-18 |
2005-12-22 |
Mehta Nozer M |
Oral delivery of peptide pharmaceutical compositions
|
|
US20070244114A1
(en)
*
|
2004-07-06 |
2007-10-18 |
Myriad Genetics, Incorporated |
Compounds and therapeutical use thereof
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
US7718658B2
(en)
*
|
2004-09-02 |
2010-05-18 |
Vertex Pharmaceuticals Incorporated |
Quinazolines useful as modulators of ion channels
|
|
US7928107B2
(en)
*
|
2004-09-02 |
2011-04-19 |
Vertex Pharmaceuticals Incorporated |
Quinazolines useful as modulators of ion channels
|
|
EP1796715A2
(en)
*
|
2004-09-22 |
2007-06-20 |
Genzyme Corporation |
USE OF TGF-ß ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
|
|
AU2005288858B2
(en)
|
2004-09-30 |
2011-04-21 |
Janssen R&D Ireland |
HCV inhibiting bi-cyclic pyrimidines
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
WO2006044433A2
(en)
*
|
2004-10-13 |
2006-04-27 |
The Ohio State University Research Foundation |
Methods to treat or prevent viral-associated lymphoproliferative disorders
|
|
US20060128702A1
(en)
*
|
2004-11-23 |
2006-06-15 |
Manojit Pal |
Heterocyclic and bicyclic compounds, compositions and methods
|
|
WO2006058012A2
(en)
*
|
2004-11-23 |
2006-06-01 |
Wyeth |
Gonadotropin releasing hormone receptor antagonists
|
|
WO2006066044A2
(en)
*
|
2004-12-17 |
2006-06-22 |
Vertex Pharmaceuticals Incorporated |
Processes for producing 4-aminoquinazolines
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
GB0428475D0
(en)
*
|
2004-12-30 |
2005-02-02 |
4 Aza Bioscience Nv |
Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
|
|
EP1844023A1
(en)
*
|
2004-12-31 |
2007-10-17 |
Sk Chemicals Co., Ltd. |
Quinazoline derivatives for the treatment and prevention of diabetes and obesity
|
|
US8258145B2
(en)
*
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
|
US7534796B2
(en)
*
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US7582634B2
(en)
*
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US7538113B2
(en)
*
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US20060189619A1
(en)
*
|
2005-02-24 |
2006-08-24 |
Wyeth |
3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
|
|
NZ556248A
(en)
*
|
2005-03-14 |
2010-06-25 |
Neurosearch As |
Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
|
|
TWI389690B
(zh)
*
|
2005-03-25 |
2013-03-21 |
Glaxo Group Ltd |
新穎化合物(一)
|
|
ES2369282T3
(es)
*
|
2005-03-25 |
2011-11-29 |
Tibotec Pharmaceuticals |
Inhibidores heterobicíclicos de vhc.
|
|
PE20100741A1
(es)
*
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
|
US20060281763A1
(en)
*
|
2005-03-25 |
2006-12-14 |
Axon Jonathan R |
Carboxamide inhibitors of TGFbeta
|
|
US20080096905A1
(en)
*
|
2005-03-25 |
2008-04-24 |
Glaxo Group Limited |
Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
|
|
WO2006100310A1
(en)
|
2005-03-25 |
2006-09-28 |
Tibotec Pharmaceuticals Ltd |
Heterobicylic inhibitors of hcv
|
|
WO2006110298A2
(en)
*
|
2005-03-25 |
2006-10-19 |
Glaxo Group Limited |
8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
|
|
US20060235020A1
(en)
*
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
|
AR056347A1
(es)
*
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
|
CN101171014B
(zh)
*
|
2005-05-12 |
2012-02-15 |
泰博特克药品有限公司 |
可用作hcv抑制剂的蝶啶类物质及其制备方法
|
|
TW200716631A
(en)
|
2005-05-12 |
2007-05-01 |
Tibotec Pharm Ltd |
Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
|
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
|
US7582636B2
(en)
*
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
DK2395004T3
(en)
|
2005-06-22 |
2016-03-21 |
Plexxikon Inc |
Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
EP1899332A1
(en)
|
2005-06-24 |
2008-03-19 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
|
|
EP1910296B1
(en)
|
2005-07-27 |
2010-04-21 |
F.Hoffmann-La Roche Ag |
4-aryloxy quinoline derivatives as 5-ht6 modulators
|
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
|
JP2009504771A
(ja)
*
|
2005-08-18 |
2009-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピラジンキナーゼ阻害剤
|
|
AU2006201635A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Ludwig Institute For Cancer Research |
Novel inhibitors and methods for their preparation
|
|
WO2007056163A2
(en)
*
|
2005-11-03 |
2007-05-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
AU2006320670B8
(en)
*
|
2005-11-30 |
2011-04-07 |
Nestec S.A. |
Methods for the treatment of muscle loss
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
BRPI0619966A2
(pt)
*
|
2005-12-16 |
2011-10-25 |
Alcon Inc |
controle de pressão intra-ocular usando agentes de modulação de alk5
|
|
EP1971611B1
(en)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Anti-viral compounds
|
|
ES2378473T3
(es)
*
|
2005-12-21 |
2012-04-12 |
Abbott Laboratories |
Compuestos antivirales
|
|
RU2467007C2
(ru)
|
2005-12-21 |
2012-11-20 |
Эбботт Лэборетриз |
Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
|
|
MX2008011136A
(es)
*
|
2006-03-07 |
2008-09-08 |
Squibb Bristol Myers Co |
Compuestos de profamarco de pirrolotriazina anilina utiles como inhibidores de cinasa.
|
|
ATE542823T1
(de)
|
2006-04-12 |
2012-02-15 |
Vertex Pharma |
4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
|
|
CN101484457B
(zh)
*
|
2006-04-12 |
2014-09-03 |
弗特克斯药品有限公司 |
作为用于治疗增殖病症的蛋白激酶PLK1抑制剂的4,5-二氢-[1,2,4]三唑并[4,3-f]蝶啶
|
|
WO2007133637A2
(en)
*
|
2006-05-10 |
2007-11-22 |
Renovis, Inc. |
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
|
|
US8338435B2
(en)
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
|
WO2008060371A1
(en)
|
2006-10-03 |
2008-05-22 |
Genzyme Corporation |
USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
|
|
EP2097084B1
(en)
*
|
2006-10-04 |
2015-01-28 |
Janssen R&D Ireland |
Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
|
|
CN101616667A
(zh)
|
2006-10-27 |
2009-12-30 |
百时美施贵宝公司 |
可用作激酶抑制剂的杂环酰胺化合物
|
|
DE602007004750D1
(de)
*
|
2006-11-02 |
2010-03-25 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
|
ES2446269T3
(es)
|
2006-12-19 |
2014-03-06 |
The Board Of Trustees Of The University Of Illinois |
3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
|
|
WO2008077086A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
US8236950B2
(en)
*
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
TW200840584A
(en)
*
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
|
WO2008077649A1
(en)
*
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infectons
|
|
WO2008077650A1
(en)
*
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
|
WO2008092942A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Neurosearch A/S |
Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
|
|
CA2677336A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
|
|
MX2009009590A
(es)
*
|
2007-03-09 |
2009-11-10 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de proteinas cinasas.
|
|
EP2134709A1
(en)
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
|
NZ579485A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
NZ580343A
(en)
|
2007-04-13 |
2012-03-30 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
|
CA2688584A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
JP5389785B2
(ja)
*
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤として有用なチアゾールおよびピラゾール
|
|
CA2694381A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
UY31137A1
(es)
*
|
2007-06-14 |
2009-01-05 |
Smithkline Beecham Corp |
Derivados de quinazolina como inhibidores de la pi3 quinasa
|
|
WO2008157500A1
(en)
*
|
2007-06-17 |
2008-12-24 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
WO2009000085A1
(en)
*
|
2007-06-27 |
2008-12-31 |
Painceptor Pharma Corporation |
Quinoline and quinazoline derivatives useful as modulators of gated ion channels
|
|
AU2008282156B2
(en)
*
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
JP2011509156A
(ja)
|
2008-01-08 |
2011-03-24 |
イェール ユニバーシティ |
血管移植片の開存性を促進するための組成物および方法
|
|
US20110053873A1
(en)
|
2008-02-01 |
2011-03-03 |
Takeda Pharmaceutical Company Limited |
Hsp90 inhibitors
|
|
PT2245026E
(pt)
|
2008-02-07 |
2012-10-15 |
Boehringer Ingelheim Int |
Heterociclos espirocíclicos, produtos farmacêuticos contendo estes compostos, sua utilização e processo para a sua preparação
|
|
US8088782B2
(en)
|
2008-05-13 |
2012-01-03 |
Astrazeneca Ab |
Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
|
|
US20100087486A1
(en)
*
|
2008-05-30 |
2010-04-08 |
Hiroshi Nakamura |
Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
|
|
EP2307411B1
(en)
|
2008-06-20 |
2014-01-01 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
|
EP2300466B1
(en)
|
2008-06-20 |
2014-08-06 |
Bristol-Myers Squibb Company |
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
|
|
WO2010002998A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
CA2735782A1
(en)
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Heterocyclic pim-kinase inhibitors
|
|
CN102215816A
(zh)
*
|
2008-09-03 |
2011-10-12 |
沃泰克斯药物股份有限公司 |
共晶和包含所述共晶的药物制剂
|
|
CN102317442B
(zh)
|
2008-12-17 |
2014-08-13 |
斯克里普斯研究所 |
干细胞的产生和保持
|
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
JP2012524073A
(ja)
*
|
2009-04-17 |
2012-10-11 |
スムマ ヘルス システムズ エルエルシー |
眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
PT3575288T
(pt)
|
2009-09-03 |
2021-12-09 |
Bristol Myers Squibb Co |
Quinazolinas como inibidores dos canais iónicos de potássio
|
|
NZ599342A
(en)
|
2009-09-25 |
2014-04-30 |
Vertex Pharma |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
|
AU2010299579A1
(en)
|
2009-09-25 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
|
US8987301B2
(en)
|
2009-11-07 |
2015-03-24 |
Merck Patent Gmbh |
Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors
|
|
WO2011092695A1
(en)
|
2010-01-28 |
2011-08-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Quinazoline-based t cell proliferation inhibitors
|
|
WO2011101069A2
(en)
*
|
2010-02-22 |
2011-08-25 |
Merck Patent Gmbh |
Hetarylaminonaphthyridines
|
|
CN102958930B
(zh)
|
2010-06-28 |
2018-04-27 |
默克专利有限公司 |
作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
|
|
WO2012027495A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of The Pacific |
Piperazinylpyrimidine analogues as protein kinase inhibitors
|
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
|
WO2012079079A1
(en)
*
|
2010-12-10 |
2012-06-14 |
President And Fellows Of Harvard College |
Production of induced pluripotent stem cells
|
|
JP5937102B2
(ja)
*
|
2010-12-14 |
2016-06-22 |
エレクトロフォレティクス リミテッド |
カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
|
|
MX2013010163A
(es)
|
2011-03-09 |
2013-10-30 |
Merck Patent Gmbh |
Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos.
|
|
US9446175B2
(en)
|
2011-06-03 |
2016-09-20 |
Yale University |
Compositions and methods for treating and preventing neointimal stenosis
|
|
EP2737083A1
(en)
|
2011-07-27 |
2014-06-04 |
INSERM (Institut National de la Santé et de la Recherche Scientifique) |
Methods for diagnosing and treating myhre syndrome
|
|
BR112014009789A2
(pt)
|
2011-10-26 |
2017-04-25 |
Seattle Children's Res Inst |
cisteamina no tratamento da doença fibrótica
|
|
US9782452B2
(en)
|
2011-11-22 |
2017-10-10 |
Cornell University |
Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
|
|
WO2013092512A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Bayer Intellectual Property Gmbh |
Substituted benzylpyrazoles
|
|
EP2843049B1
(en)
*
|
2012-04-27 |
2018-04-11 |
Keio University |
Neuronal differentiation promoter
|
|
WO2014022728A1
(en)
|
2012-08-02 |
2014-02-06 |
Endo Pharmaceuticals, Inc |
Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
|
|
EP2900666B1
(en)
*
|
2012-09-28 |
2020-11-04 |
Cancer Research Technology Limited |
Azaquinazoline inhibitors of atypical protein kinase c
|
|
US20140127228A1
(en)
*
|
2012-11-02 |
2014-05-08 |
Indiana University School of Medicine |
Inhibition of tgfbeta signaling to improve muscle function in cancer
|
|
BR112015023261A2
(pt)
|
2013-03-14 |
2017-07-18 |
Massachusetts Inst Technology |
composições e métodos para expansão e cultura de células-tronco epiteliais
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
US9815797B2
(en)
|
2013-12-09 |
2017-11-14 |
Ucb Biopharma Sprl |
Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
|
|
LT3089971T
(lt)
|
2014-01-01 |
2020-10-12 |
Medivation Technologies Llc |
Junginiai ir panaudojimo būdai
|
|
KR102405136B1
(ko)
|
2014-05-16 |
2022-06-07 |
아트리바 테라퓨틱스 게엠베하 |
인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략
|
|
KR102493376B1
(ko)
|
2014-09-03 |
2023-01-27 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
|
|
CN104496915B
(zh)
*
|
2014-12-19 |
2017-05-03 |
华侨大学 |
一种喹唑啉酮芳香化合物的合成方法
|
|
US11021468B2
(en)
|
2015-04-01 |
2021-06-01 |
Rigel Pharmaceuticals, Inc. |
TGF-ß inhibitors
|
|
EP3313420B1
(en)
|
2015-06-25 |
2024-03-13 |
The Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
|
EP3386556A4
(en)
|
2015-12-11 |
2019-07-31 |
Research Institute at Nationwide Children's Hospital |
SYSTEMS AND METHOD FOR OPTIMIZED PATIENT-SPECIFIC TISSUE-RENEWED TISSUE TRANSPLANTS
|
|
JP2019506153A
(ja)
|
2016-01-08 |
2019-03-07 |
マサチューセッツ インスティテュート オブ テクノロジー |
分化した腸内分泌細胞およびインスリン産生細胞の作製
|
|
US11260130B2
(en)
|
2016-03-02 |
2022-03-01 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
|
|
US10213511B2
(en)
|
2016-03-02 |
2019-02-26 |
Frequency Therapeutics, Inc. |
Thermoreversible compositions for administration of therapeutic agents
|
|
US10201540B2
(en)
|
2016-03-02 |
2019-02-12 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
|
|
AU2017235461B2
(en)
|
2016-03-15 |
2023-02-23 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
|
KR101965642B1
(ko)
|
2016-08-23 |
2019-08-13 |
김유신 |
목재 해충 처리용 스팀 건 및 이를 이용한 해충 처리방법
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
US10016425B2
(en)
|
2016-11-03 |
2018-07-10 |
King Saud University |
Anti-ulcerative colitis compound
|
|
CA3048220A1
(en)
|
2016-12-30 |
2018-07-05 |
Frequency Therapeutics, Inc. |
1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
CA3127373A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
|
|
AU2019240065A1
(en)
|
2018-03-20 |
2020-09-24 |
Icahn School Of Medicine At Mount Sinai |
Kinase inhibitor compounds and compositions and methods of use
|
|
US20210254006A1
(en)
|
2018-06-06 |
2021-08-19 |
Ideaya Biosciences, Inc. |
Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
|
|
CN108727283B
(zh)
*
|
2018-06-14 |
2021-03-02 |
温州医科大学附属第一医院 |
一种苯磺酰氨类抗炎化合物的合成方法
|
|
CN108912061B
(zh)
*
|
2018-06-14 |
2021-03-19 |
温州医科大学 |
一种喹唑啉类炎症抑制化合物的合成方法
|
|
CN109053597B
(zh)
*
|
2018-06-14 |
2021-03-19 |
温州医科大学附属第二医院、温州医科大学附属育英儿童医院 |
一种炎症抑制化合物及其制备方法
|
|
CN108912059B
(zh)
*
|
2018-06-14 |
2021-03-02 |
温州医科大学附属第一医院 |
一种含氮杂环炎症抑制化合物的合成方法
|
|
CN108727282B
(zh)
*
|
2018-06-14 |
2021-03-02 |
温州医科大学附属第一医院 |
一种含苯磺酰氨基的抗炎化合物及其合成方法
|
|
CN108912060B
(zh)
*
|
2018-06-14 |
2021-03-19 |
温州医科大学 |
一种喹唑啉类抗炎化合物及其合成方法
|
|
EP3837351A1
(en)
|
2018-08-17 |
2021-06-23 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by downregulating foxo
|
|
CA3109647A1
(en)
|
2018-08-17 |
2020-02-20 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by upregulating jag-1
|
|
CA3124700A1
(en)
|
2018-12-31 |
2020-07-09 |
Icahn School Of Medicine At Mount Sinai |
Kinase inhibitor compounds and compositions and methods of use
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
US20240166669A1
(en)
*
|
2021-03-05 |
2024-05-23 |
Nikang Therapeutics, Inc. |
Quinazoline amine derivatives as kras inhibitors
|
|
CA3211872A1
(en)
*
|
2021-03-24 |
2022-09-29 |
Athos Therapeutics, Inc. |
Small molecules for the treatment of kinase-related diseases
|
|
WO2023280911A1
(en)
|
2021-07-06 |
2023-01-12 |
Westfälische Wilhelms-Universität Münster |
P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
|
|
US20240300905A1
(en)
*
|
2023-02-21 |
2024-09-12 |
Prosetta Biosciences, Inc. |
Quinazoline Compounds and Uses
|
|
WO2024243025A1
(en)
*
|
2023-05-19 |
2024-11-28 |
Ikena Oncology, Inc. |
Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
|
|
WO2025009910A1
(ko)
*
|
2023-07-04 |
2025-01-09 |
부산대학교 산학협력단 |
퀴나졸린 유도체 화합물 및 이의 용도
|
|
CN119161336B
(zh)
*
|
2024-07-24 |
2025-09-05 |
四川大学 |
一种作为Blimp1抑制剂的小分子化合物及其用途
|